vTv Therapeutics Inc. (NASDAQ:VTVT) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of vTv Therapeutics Inc. (NASDAQ:VTVT) have been assigned a consensus rating of “Moderate Buy” from the seven ratings firms that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, five have issued a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $53.00.

A number of equities research analysts recently weighed in on the stock. Weiss Ratings raised shares of vTv Therapeutics from a “sell (d-)” rating to a “sell (d+)” rating in a report on Monday, May 18th. Zacks Research upgraded shares of vTv Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, May 13th. Evercore began coverage on shares of vTv Therapeutics in a research note on Thursday, March 12th. They set an “outperform” rating and a $44.00 price objective on the stock. Wall Street Zen upgraded shares of vTv Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, May 16th. Finally, BTIG Research reiterated a “buy” rating and set a $49.00 price objective on shares of vTv Therapeutics in a research note on Wednesday, March 11th.

vTv Therapeutics Stock Performance

Shares of VTVT stock opened at $32.94 on Thursday. vTv Therapeutics has a one year low of $14.00 and a one year high of $44.00. The company has a 50 day moving average price of $35.56 and a 200 day moving average price of $35.00. The firm has a market capitalization of $129.78 million, a price-to-earnings ratio of -35.42 and a beta of 0.27.

vTv Therapeutics (NASDAQ:VTVT) last released its quarterly earnings data on Wednesday, May 13th. The biotechnology company reported $1.65 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.21 by $1.44. The business had revenue of $36.84 million during the quarter, compared to analyst estimates of $20.00 million. As a group, equities analysts forecast that vTv Therapeutics will post -2.19 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. 683 Capital Management LLC acquired a new position in shares of vTv Therapeutics in the 4th quarter valued at about $731,000. Goldman Sachs Group Inc. acquired a new position in shares of vTv Therapeutics in the 4th quarter valued at about $221,000. Geode Capital Management LLC boosted its holdings in shares of vTv Therapeutics by 84.3% in the 4th quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock valued at $1,128,000 after buying an additional 12,896 shares during the period. Finally, Baker BROS. Advisors LP lifted its position in vTv Therapeutics by 52.4% in the 3rd quarter. Baker BROS. Advisors LP now owns 148,314 shares of the biotechnology company’s stock valued at $3,463,000 after purchasing an additional 51,000 shares during the last quarter. 17.51% of the stock is owned by institutional investors and hedge funds.

vTv Therapeutics Company Profile

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.